Nathaniel A Sowa1, Angela Bengtson2, Bradley N Gaynes3, Brian W Pence2. 1. Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Electronic address: nathaniel_sowa@med.unc.edu. 2. Department of Epidemiology, University of North Carolina School of Public Health, Chapel Hill, NC, USA. 3. Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
Abstract
BACKGROUND: Treatment of comorbid chronic disease, such as depression, in people living with HIV/AIDS (PLWHA) increasingly falls to HIV treatment providers. Guidance in who will best respond to depression treatment and which patient-centered symptoms are best to target is limited. METHODS: Bivariable analyses were used to calculate hazard ratios for associations between baseline demographic, mental health-related, and HIV-related factors on time to first depression remission among PLWHA enrolled in a randomized trial of measurement-based antidepressant management. Time-updated factors also were analyzed at time of antidepressant (AD) initiation/adjustment and 8 weeks post AD initiation/adjustment. RESULTS:Baseline comorbid depression and anxiety; comorbid depression, anxiety and substance abuse; and generalized anxiety disorder predicted a slower time to first remission. Being on ART but non-adherent, having panic disorder, having a history of a major depressive episode, or having been in HIV care for >10 years prior to study initiation predicted a faster time to first remission. Sleep difficulty or fatigue at the time of AD initiation/adjustment predicted a slower time to remission. In non-remitters at 8 weeks post AD initiation/adjustment, sleep difficulty, anxiety, and fatigue each predicted a slower time to remission. LIMITATIONS: Remission was determined by PHQ-9 scores, not diagnostic criteria. The results may apply only to depression recovery in this particular model of treatment. We conducted only exploratory analyses to determine magnitude of effects. CONCLUSIONS: Baseline comorbid anxiety with or without substance abuse predicts slower time to depression remission among PLWHA treated in HIV clinics. Targeting anxiety or fatigue at the time of AD initiation/adjustment or sleep difficulty, anxiety, and fatigue at 8 weeks post AD initiation/adjustment could shorten time to depression remission in this model.
RCT Entities:
BACKGROUND: Treatment of comorbid chronic disease, such as depression, in people living with HIV/AIDS (PLWHA) increasingly falls to HIV treatment providers. Guidance in who will best respond to depression treatment and which patient-centered symptoms are best to target is limited. METHODS: Bivariable analyses were used to calculate hazard ratios for associations between baseline demographic, mental health-related, and HIV-related factors on time to first depression remission among PLWHA enrolled in a randomized trial of measurement-based antidepressant management. Time-updated factors also were analyzed at time of antidepressant (AD) initiation/adjustment and 8 weeks post AD initiation/adjustment. RESULTS: Baseline comorbid depression and anxiety; comorbid depression, anxiety and substance abuse; and generalized anxiety disorder predicted a slower time to first remission. Being on ART but non-adherent, having panic disorder, having a history of a major depressive episode, or having been in HIV care for >10 years prior to study initiation predicted a faster time to first remission. Sleep difficulty or fatigue at the time of AD initiation/adjustment predicted a slower time to remission. In non-remitters at 8 weeks post AD initiation/adjustment, sleep difficulty, anxiety, and fatigue each predicted a slower time to remission. LIMITATIONS: Remission was determined by PHQ-9 scores, not diagnostic criteria. The results may apply only to depression recovery in this particular model of treatment. We conducted only exploratory analyses to determine magnitude of effects. CONCLUSIONS: Baseline comorbid anxiety with or without substance abuse predicts slower time to depression remission among PLWHA treated in HIV clinics. Targeting anxiety or fatigue at the time of AD initiation/adjustment or sleep difficulty, anxiety, and fatigue at 8 weeks post AD initiation/adjustment could shorten time to depression remission in this model.
Authors: Jeffrey M Pyne; John C Fortney; Geoffrey M Curran; Shanti Tripathi; J H Atkinson; Amy M Kilbourne; Hildi J Hagedorn; David Rimland; Maria C Rodriguez-Barradas; Thomas Monson; Kathryn A Bottonari; Steven M Asch; Allen L Gifford Journal: Arch Intern Med Date: 2011-01-10
Authors: Wayne J Katon; Elizabeth H B Lin; Michael Von Korff; Paul Ciechanowski; Evette J Ludman; Bessie Young; Do Peterson; Carolyn M Rutter; Mary McGregor; David McCulloch Journal: N Engl J Med Date: 2010-12-30 Impact factor: 91.245
Authors: Wayne J Katon; Michael Von Korff; Elizabeth H B Lin; Greg Simon; Evette Ludman; Joan Russo; Paul Ciechanowski; Edward Walker; Terry Bush Journal: Arch Gen Psychiatry Date: 2004-10
Authors: Brian W Pence; Jon C Mills; Angela M Bengtson; Bradley N Gaynes; Tiffany L Breger; Robert L Cook; Richard D Moore; David J Grelotti; Conall O'Cleirigh; Michael J Mugavero Journal: JAMA Psychiatry Date: 2018-04-01 Impact factor: 21.596
Authors: Bethany L DiPrete; Brian W Pence; Angela M Bengtson; Richard D Moore; David J Grelotti; Conall O'Cleirigh; Riddhi Modi; Bradley N Gaynes Journal: AIDS Behav Date: 2019-03
Authors: L E Gibbons; R Fredericksen; D S Batey; L Dant; T C Edwards; K H Mayer; W C Mathews; L S Morales; M J Mugavero; F M Yang; E Paez; M M Kitahata; D L Patrick; H M Crane; P K Crane Journal: AIDS Res Ther Date: 2017-04-11 Impact factor: 2.250